Darrin Uecker - Nov 1, 2023 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role
Chief Technology Officer, Director
Signature
/s/ Kenneth B. Stratton, as Attorney-in-Fact
Stock symbol
PLSE
Transactions as of
Nov 1, 2023
Transactions value $
$0
Form type
4
Date filed
11/3/2023, 05:36 PM
Previous filing
Jul 14, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLSE Stock Option (right to buy) Award $0 +330K $0.00 330K Nov 1, 2023 Common Stock 330K $4.38 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 100% vesting upon the earlier of (i) the six (6) year anniversary of the grant date, and (ii) the 1-year anniversary of a Company change of control.